UBS upgraded West Pharmaceutical (WST) to Buy from Neutral with a price target of $390, up from $350. The firm has incremental confidence in a positive mix shift driven by Annex 1 regulations, wearable injectors, and GLP-1 tailwinds, and tells investors in a research that coupled with a view that destocking headwinds should dissipate soon, the combination drives confidence West can return to long- range plan growth earlier than expected, driving stock performance.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks